{"prompt": "['20', 'IV: Design', '4.1: Study design', 'The study will be performed as a controlled, open and non-randomized, stratified', 'observational multicenter. The two stratification factors will be ophthalmological diagnose', 'and the severity of the disease.', 'Baseline &', 'Stability', 'Repeatability', 'Health Control', '1*', '2', 'Diabetes', 'Mild', '1*', '2', '3', '4', '5', '6', 'Retinopathy', 'Moderate', '1*', '2', '3', '4', '5', '6', 'Pathology', 'Health Control', '1 *', '2', 'Age related', 'macular', 'Early', '1 *', '2', '3', '4', '5', '6', 'degeneration', '(AMD)', 'Intermediate', '1*', '2', '3', '4', '5', '6', 'Time schedule (Day):', 'Day 1', 'Day 2', 'Day 3', 'Figure 1: The overall study design. The numbers 1 to 6 indicate the sequence of Bulbicam', 'measurements and *) the measurements using the Standard Method', '4.2: Stratification', 'The two main strata are DR and AMD. The patients within each of these two strata will be', 'divided in two sub-strata depending on the disease severity. Within each of the main strata, a', 'third stratum will consist of gender- and age-matched HCs to the patients included in the two', 'other sub-strata.', 'The three sub-strata within DR will be:', '1.', 'Healthy gender- and age-matched controls', '2. Mild retinopathy: Mild nonproliferative retinopathy', '3. Moderate retinopathy: Moderate nonproliferative retinopathy', 'The three sub-strata within AMD will be:', 'BulbiCam; Validity study:', '71_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']['21', '1. Healthy gender- and age-matched controls', '2. Early AMD', '3. Intermediate AMD', '4.3: Identification of patients', 'All information in the database will be anonymized and the activation key is stored by the', 'clinically responsible ophthalmologist. The patients will be given one study identification', 'number of six digits. The Id-number is divided in two parts in which the first part consists of', 'four digits based on; country; site; disease and degree of the disease. Within these four-digit', 'groups, two digits running number will be created by the DB-system.', 'Digit 1:', 'Indicate the country [1=Norway; 2=India i.e.]', 'Digit 2:', 'Indicate hospital site [1 = Site 1/Ulleval; 2= Site 2/Helgeland i.e.]', 'Digit 3:', 'Disease [0= Control; 1=Gla; 2=Cat; 3=DR; 4=AMD; 5=MS, i.e.].', 'Digit 4:', 'Degree of disease [0= none; 1= Mild/Early; 2=Moderate/Intermediate;', '3=Severe].', 'Digit 5&6:', 'Running number within group [01 = Patient 1; 02=Patient 2 i.e.]', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']['22', 'V: Evaluation', '5.1: Main variables', '5.1.1: BulbiCam investigation', 'The main variables will be the variables recorded at the six Bulbicam tests described in the', 'table below:', 'Table 2: The main variables with unit of the six Bulbicam test included in the study', 'TEST', 'VARIABLE', 'UNIT', 'FORMAT', 'Seen/unseen (0)', '0= unseen target', 'xml.', 'NeuroField64', 'Saccadic Reaction Time', 'Ms - 4 digits, 0 decimals', 'xml.', 'Angular deviation', 'degree - 3 digits, 0 decimals', 'xml.', 'MDR1', 'mm - 2 digits, 2 decimals', 'xml.', 'Ptosis', 'MDR2', 'mm - 2 digits, 2 decimals', 'xml.', 'Dynamic Acuity', 'Visual acuity', 'LogMAR 1 digit, 2 decimals', 'xml.', 'Dynamic Contrast', 'Contrast sensitivity', 'ConRatio 1 digit, 2 decimals', 'xml.', 'Fixed contrast', 'Hz 1 digit, 1 decimal', 'xml.', 'Dark Adaptation', 'Fixed frequency', 'ConRatio 1 digit, 2 decimals', 'xml.', 'Diameter (mm)', 'mm - 1 digit, 2 decimals', 'xml.', 'Pupil', 'Peak velocity', 'mm/s - 1 digit, 2 decimals', 'xml.', 'Latency', 'Ms 3 digits, 0 decimals', 'xml.', 'RAPDlog', '1 digit, 2 decimals', 'xml.', 'For Pupil module, a typical continuous recording of the pupil size and parameters is shown', 'below:', '3', '2', 'o', '20', '21', '22', '23', 'OD', 'OS', 'Round', '2 Round', 'DIAMETER (MM)', 'LIGHT ON os LIGHT ON OD', 'LIGHT ON os LIGHT ON OD', 'LATENCY (MS)', 'OD 3.93 3.91 2.46 2.59', '2.85 2.79 -0.05 -0.01 2.90', '2.80', '2.78', '3.00', '-0.16', '0.10', '2.95', '2.90', '365', '362', '369', '384', '374', '388', 'os 4.15 4.07 2.54 2.63', '2.87 2.83 -0.11 -0.03 2.98', '2.86', '2.75', '3.01', '-0.28', '-0.01', '3.03', '3.02', '360', '371', '369', '384', '364', '338', 'DELTA -0.22 -0.16 -0.08 -0.04', '-0.02 -0.04', '-0.08 -0.06', '0.03 -0.01', '-0.09 -0.12', '-5.02', '9.03', '0.00', '0.00', '-9.38-49.55', 'LogCon defined as -log10 (contrast ratio), EG if the low brightness part of the stimulus is 2', 'nits, the high brightness part 255 nits, the LogCon would be - -log10 (2/255) =2, 1.', '5.1.2: Standard investigation', 'The supporting variables will be recorded by the Standard (ST) investigation for DR and', 'AMD.', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']\n\n###\n\n", "completion": "END"}